Skip to main content

Table 7 Association of PD-L1 staining with estrogen receptor/progesterone receptor-positive and triple-negative status in sTIL subgroups in patients without neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

sTIL < 10%sTIL ≥10%sTIL < 10%sTIL ≥10%sTIL < 10%sTIL ≥10%
ER/PR pos195102613188171722195101821
Fisher P value0.60440.11210.37870.49170.60440.6509
  1. ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, sTIL stromal tumor infiltrating lymphocytes, pos positive, neg negative